Menu

Comment on New NIH Center

Input lines are open for the National Institute of Substance Use and Addiction Disorders.

Feb 10, 2012
Megan Scudellari

NIH Campus

The National Institutes of Health is seeking input from the scientific community on the new National Institute of Substance Use and Addiction Disorders (working title), scheduled to open in 2014.

The proposed institute is the result of a November 2010 recommendation from the Scientific Management Review Board that the NIH should reorganize all substance use, abuse, and addiction-related research at the Institutes. Both the National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism will be dissolved and their research programs folded into the new institute.

The NIH is asking for comments about “potential scientific opportunities and public health needs” that should be included in the new Institute’s strategic plan. Those comments can be submitted electronically, and will be accepted through May 11, 2012. The NIH will also conduct a series of public meetings to discuss the new Institute, which will be posted on the NIH’s feedback website.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.